[go: up one dir, main page]

DK1303591T3 - MASP-2, a complement-fixing enzyme, and uses thereof - Google Patents

MASP-2, a complement-fixing enzyme, and uses thereof

Info

Publication number
DK1303591T3
DK1303591T3 DK01957763T DK01957763T DK1303591T3 DK 1303591 T3 DK1303591 T3 DK 1303591T3 DK 01957763 T DK01957763 T DK 01957763T DK 01957763 T DK01957763 T DK 01957763T DK 1303591 T3 DK1303591 T3 DK 1303591T3
Authority
DK
Denmark
Prior art keywords
masp
relates
present
fragments
inhibitors
Prior art date
Application number
DK01957763T
Other languages
Danish (da)
Inventor
Steffen Thiel
Jens Christian Jensenius
Original Assignee
Helion Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helion Biotech Aps filed Critical Helion Biotech Aps
Application granted granted Critical
Publication of DK1303591T3 publication Critical patent/DK1303591T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

The present invention relates to substantially pure mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and/or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comparing such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.
DK01957763T 2000-07-13 2001-07-13 MASP-2, a complement-fixing enzyme, and uses thereof DK1303591T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001089 2000-07-13
DKPA200100870 2001-06-01
PCT/DK2001/000499 WO2002006460A2 (en) 2000-07-13 2001-07-13 Masp-2, a complement-fixing enzyme, and uses for it

Publications (1)

Publication Number Publication Date
DK1303591T3 true DK1303591T3 (en) 2009-11-02

Family

ID=26068853

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01957763T DK1303591T3 (en) 2000-07-13 2001-07-13 MASP-2, a complement-fixing enzyme, and uses thereof

Country Status (13)

Country Link
US (1) US7112414B2 (en)
EP (1) EP1303591B1 (en)
JP (1) JP5226169B2 (en)
CN (1) CN1449440A (en)
AT (1) ATE434661T1 (en)
AU (1) AU2001279586A1 (en)
CA (2) CA2415751C (en)
DE (1) DE60139072D1 (en)
DK (1) DK1303591T3 (en)
NO (1) NO20030114L (en)
NZ (1) NZ523900A (en)
RU (1) RU2003104524A (en)
WO (1) WO2002006460A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
SE0202880D0 (en) * 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
CN1694961A (en) * 2002-09-10 2005-11-09 内蒂穆恩公司 Collectin-complement activating protein chimeras
WO2004050907A2 (en) * 2002-12-03 2004-06-17 Aarhus Universitet Method for determing predisposition to manifestation of immune system related diseases
WO2004065626A2 (en) * 2003-01-17 2004-08-05 Rigshospitalet A method of sepsis prognosis
EP1601377A4 (en) 2003-02-21 2009-07-15 Genentech Inc Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
PT2374819T (en) * 2003-05-12 2017-07-04 Helion Biotech Aps Antibodies to masp-2
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
EP2446902A1 (en) * 2004-06-10 2012-05-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201558B2 (en) * 2004-06-10 2016-03-31 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
DE602005015756D1 (en) * 2004-12-23 2009-09-10 Tno METHOD FOR THE FUNCTIONAL DETECTION OF MASPS AND ITS COMPLEXES
US8524453B2 (en) * 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
CN101587125B (en) * 2008-05-21 2013-07-24 林标扬 High expression cancer marker and low expression tissue organ marker kit
CN102712687A (en) 2009-07-17 2012-10-03 丹麦国家医院 MASP isoforms as inhibitors of complement activation
PT2488203T (en) * 2009-10-16 2017-03-10 Univ Leicester Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
AU2013201443B2 (en) * 2009-10-16 2015-02-05 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX355648B (en) 2011-04-08 2018-04-26 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation.
RS60541B1 (en) * 2011-05-04 2020-08-31 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
MX2016009850A (en) * 2014-01-29 2017-02-17 Enzymatica Ab Novel treatments.
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
CN112237630A (en) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 Application of MASP-2, coronavirus N protein or their combined substances in the preparation of drugs for diseases caused by coronavirus
WO2021163980A1 (en) * 2020-02-21 2021-08-26 中国人民解放军军事科学院军事医学研究院 Substance targeting masp-2 and n protein or binding thereof for preventing and/or treating coronavirus infection
CN112023045A (en) * 2020-03-31 2020-12-04 中国人民解放军军事科学院军事医学研究院 Application of substance for inhibiting MASP-2 and downstream complement activation effect thereof in preparation of drugs for treating diseases caused by coronavirus
EP4493597A1 (en) * 2022-03-18 2025-01-22 Inmagene Pte. Ltd. Masp-2-targetting antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
US6008017A (en) * 1997-01-02 1999-12-28 Smithkline Beecham Corporation Human cardiac/brain tolloid-like protein
US5955309A (en) * 1997-06-18 1999-09-21 Smithkline Beecham Corporation Polynucleotide encoding G-protein coupled receptor (H7TBA62)
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
CA2347734A1 (en) * 1998-12-15 2000-06-22 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US6235494B1 (en) * 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1218406A1 (en) 1999-08-11 2002-07-03 Curagen Corporation Nucleic acids and secreted polypeptides encoded thereby
AU781805B2 (en) * 1999-08-13 2005-06-16 Brigham And Women's Hospital Inhibitors of the lectin complement pathway (LCP) and their use
CA2391402A1 (en) * 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it

Also Published As

Publication number Publication date
CA2887012A1 (en) 2002-01-24
WO2002006460A3 (en) 2002-05-02
CN1449440A (en) 2003-10-15
US7112414B2 (en) 2006-09-26
ATE434661T1 (en) 2009-07-15
US20040038297A1 (en) 2004-02-26
NZ523900A (en) 2004-02-27
WO2002006460A2 (en) 2002-01-24
CA2415751C (en) 2015-06-16
NO20030114L (en) 2003-02-25
JP5226169B2 (en) 2013-07-03
AU2001279586A1 (en) 2002-01-30
DE60139072D1 (en) 2009-08-06
EP1303591A2 (en) 2003-04-23
EP1303591B1 (en) 2009-06-24
JP2004504027A (en) 2004-02-12
RU2003104524A (en) 2005-01-20
NO20030114D0 (en) 2003-01-09
CA2415751A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
DK1303591T3 (en) MASP-2, a complement-fixing enzyme, and uses thereof
HK1096427A1 (en) Novel fungal proteins and nucleic acids encoding same
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ781143A (en) Anti-vegf protein compositions and methods for producing the same
DE60134786D1 (en) MINI-DYSTROPHINE NUCLEIC ACID AND PEPTIDE SEQUENCES
MY120693A (en) Human bikunin
DK1349944T3 (en) Latency-associated peptide of TGF-beta to confer latency to pharmaceutically active proteins
DE60330346D1 (en) MULTI-SUBSTITUTED PROTEASE VERSIONS
HUP0400588A2 (en) Von willebrand factor (vwf) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide
DK2060628T3 (en) Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
ATE350470T1 (en) CHIMERIC PROTEINS CLIPABLE BY THROMBIN
Jedličková et al. Major acid endopeptidases of the blood-feeding monogenean Eudiplozoon nipponicum (Heteronchoinea: Diplozoidae)
WO2000001831A3 (en) Proteases fused with variants of streptomyces subtilisin inhibitor
ATE323763T1 (en) DNA & PROTEIN BINDING MINIATURE PROTEINS
Caglič et al. Fungal β-trefoil trypsin inhibitors cnispin and cospin demonstrate the plasticity of the β-trefoil fold
Henschen et al. Fibrinogen evolution: intra-and inter-species comparisons
BRPI0409557A (en) recombinant kallikrein inhibitor protein, DNA sequence, expression vector, host cell, pharmaceutical composition and its use, production method of recombinant kallikrein inhibitor protein and diagnostic kit for detection of kallikrein
DK1051495T3 (en) Recombinant mistletoe lectins
Kubota et al. Stability profiles of nepenthesin in urea and guanidine hydrochloride: comparison with porcine pepsin A
EA200601749A1 (en) COSPEPTIN, COSMEDINE AND THEIR APPLICATIONS
Wang et al. Design of peptide inhibitors for furin based on the C‐terminal fragment of histone H1. 2
Fló et al. The monodomain Kunitz protein Eg KU-7 from the dog tapeworm Echinococcus granulosus is a high-affinity trypsin inhibitor with two interaction sites
ATE435914T1 (en) INDUCTION OF FLOWER FORMATION
JP2005513141A (en) Modified tridegins, their formulations, and their use as transglutaminase inhibitors
Midura-Nowaczek et al. Synthesis of benzylamides of dipeptides as potential inhibitors of plasmin